KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $5.1 billion.

  • Vertex Pharmaceuticals' Cash & Equivalents rose 1127.45% to $5.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.1 billion, marking a year-over-year increase of 1127.45%. This contributed to the annual value of $5.1 billion for FY2025, which is 1127.45% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Cash & Equivalents stood at $5.1 billion for Q4 2025, which was up 1127.45% from $4.9 billion recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash & Equivalents peaked at $11.1 billion during Q3 2023, and registered a low of $4.6 billion during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $7.3 billion, with a median of $6.5 billion in 2021.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Cash & Equivalents soared by 7544.05% in 2021, and later tumbled by 5593.06% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash & Equivalents (Quarter) stood at $6.8 billion in 2021, then surged by 54.58% to $10.5 billion in 2022, then dropped by 1.28% to $10.4 billion in 2023, then plummeted by 55.93% to $4.6 billion in 2024, then rose by 11.27% to $5.1 billion in 2025.
  • Its Cash & Equivalents stands at $5.1 billion for Q4 2025, versus $4.9 billion for Q3 2025 and $5.0 billion for Q2 2025.